Latest Headlines

Latest Headlines

Turnaround-minded Teva CEO scouts deals in specialty generics, emerging markets

With a bounce-back in share price, Teva's in a position to do something it hasn't done much over the past few years: buy companies. And when it comes to getting back into the M&A game, CEO Erez Vigodman has a few types of targets at the top of his list.

Banks lost big betting on canceled AbbVie-Shire merger

The ripple effects of AbbVie's canceled Shire deal extend beyond the disgruntled hedge fund managers and spooked investors who've been making noise since the $55 billion buyout collapsed. Several large investment banks lost money, too, raising eyebrows over whether they're illegally betting their own funds.

Investor cries foul over Covance's $6B sale to LabCorp

Covance got some bad advice when it agreed to a roughly $6 billion buyout from LabCorp, according to an investor lawsuit, which alleges that chief dealbroker Goldman Sachs had a conflict of interest all along.

UPDATED: Will the $8.2B buyout of PetSmart affect its in-store Banfield pet hospitals?

Today Wall Street is chewing on the news that PetSmart has agreed to be acquired in an $8.2 billion private equity deal--the largest such deal of 2014. But what will the buyout mean for the company's presence in animal health, namely the veterinary clinics that it operates in more than 850 of its stores?

Medidata burnishes its risk-based monitoring tech with latest buy

Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.

Abbott, unfazed by political tensions, closes deal for Russia's Veropharm

Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook Abbott Laboratories out of its VeroPharm buy, it announced Friday.

No pharma companies will get Danone's medical nutrition biz, because it is not for sale

For months analysts have been handicapping who might buy Danone's medical nutrition business. Hospira was cited as a possible buyer for tax inversion reasons and then Fresenius was said to want it, but was getting frustrated with protracted talks. It turns out, after 8 months of speculation, that no one will get it.

Shire CEO eyes $10B sales goal with more M&A deals in mind

Shire is enjoying the single life post-AbbVie breakup, touting its newly independent status and beefing up R&D. But if the company wants to beat its already ambitious sales goals, some strategic dealmaking could be on the horizon, CEO Flemming Ornskov says.

Sanofi chairman hints at animal health deals, sending Zoetis shares soaring

On Wednesday, Sanofi Chairman and acting CEO Serge Weinberg told the German publication Handelsblatt that the company is looking for growth in its veterinary products unit--and that the expansion could come in the form of acquisitions.

Up almost one-third in 2014, Cantel falls on Q1 earnings miss

Cantel Medical is up about 30% this year on investor enthusiasm for its sales growth in endoscopy, as well as a brisk acquisition strategy. But its shares were down about 1% in early trading on Dec. 10 after the company reported first quarter earnings that missed expectations a bit.